Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies

• Published in: Journal for immunotherapy of cancer 2019-09, Vol.7 (1), p.244-244, Article 244
• Main Authors: Mullins, Stefanie R., Vasilakos, John P., Deschler, Katharina, Grigsby, Iwen, Gillis, Pete, John, Julius, Elder, Matthew J., Swales, John, Timosenko, Elina, Cooper, Zachary, Dovedi, Simon J., Leishman, Andrew J., Luheshi, Nadia, Elvecrog, James, Tilahun, Ashenafi, Goodwin, Richard, Herbst, Ronald, Tomai, Mark A., Wilkinson, Robert W.
• Format: Article
• Language: English
• Subjects: Antibodies; Antigens; Cancer; Cancer therapies; Care and treatment; Clinical/Translational Cancer Immunotherapy; Cloning; Cytokines; Dendritic cells; Flow cytometry; Gene expression; Health aspects; Immune checkpoint blockade; Immune response; Immunotherapy; Laboratories; Lymphocytes; Monoclonal antibodies; Peptides; Research Article; Skin cancer; T cell; T cell agonist; T cells; TLR; Tumors
• ISSN: 2051-1426; 2051-1426
• DOI: 10.1186/s40425-019-0724-8

BackgroundImmune checkpoint blockade (ICB) promotes adaptive immunity and tumor regression in some cancer patients. However, in patients with immunologically “cold” tumors, tumor-resident innate immune cell activation may be required to prime an adaptive immune response and so exploit the full potential of ICB. Whilst Toll-like receptor (TLR) agonists have been used topically to successfully treat some superficial skin tumors, systemic TLR agonists have not been well-tolerated.MethodsThe response of human immune cells to TLR7 and 8 agonism was measured in primary human immune cell assays. MEDI9197 (3M-052) was designed as a novel lipophilic TLR7/8 agonist that is retained at the injection site, limiting systemic exposure. Retention of the TLR7/8 agonist at the site of injection was demonstrated using quantitative whole-body autoradiography, HPLC-UV, and MALDI mass spectrometry imaging. Pharmacodynamic changes on T cells from TLR7/8 agonist treated B16-OVA tumors was assessed by histology, quantitative real time PCR, and flow cytometry. Combination activity of TLR7/8 agonism with immunotherapies was assessed in vitro by human DC-T cell MLR assay, and in vivo using multiple syngeneic mouse tumor models.ResultsTargeting both TLR7 and 8 triggers an innate and adaptive immune response in primary human immune cells, exemplified by secretion of IFNα, IL-12 and IFNγ. In contrast, a STING or a TLR9 agonist primarily induces release of IFNα. We demonstrate that the TLR7/8 agonist, MEDI9197, is retained at the sight of injection with limited systemic exposure. This localized TLR7/8 agonism leads to Th1 polarization, enrichment and activation of natural killer (NK) and CD8+ T cells, and inhibition of tumor growth in multiple syngeneic models. The anti-tumor activity of this TLR7/8 agonist is enhanced when combined with T cell-targeted immunotherapies in pre-clinical models.ConclusionLocalized TLR7/8 agonism can enhance recruitment and activation of immune cells in tumors and polarize anti-tumor immunity towards a Th1 response. Moreover, we demonstrate that the anti-tumor effects of this TLR7/8 agonist can be enhanced through combination with checkpoint inhibitors and co-stimulatory agonists.